Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing, China.
Laboratory of Quality & Safety Risk Assessment for Animal Products on Chemical Hazards (Beijing), Ministry of Agriculture and Rural affairs, Beijing, China.
J Vet Pharmacol Ther. 2020 Jul;43(4):364-368. doi: 10.1111/jvp.12852. Epub 2020 Mar 11.
The pharmacokinetic properties of three formulations of vitacoxib were investigated in horses. To describe plasma concentrations and characterize the pharmacokinetics, 6 healthy adult Chinese Mongolian horses were administered a single dose of 0.1 mg/kg bodyweight intravenous (i.v.), oral paste, or oral tablet vitacoxib in a 3-way, randomized, parallel design. Blood samples were collected prior to and at various times up to 72 hr postadministration. Plasma vitacoxib concentrations were quantified using UPLC-MS/MS, and pharmacokinetic parameters were calculated using noncompartmental analysis. No complications resulting from the vitacoxib administration were noted on subsequent administrations, and all procedures were tolerated well by the horses throughout the study. The elimination half-life (T ) was 4.24 ± 1.98 hr (i.v.), 8.77 ± 0.91 hr (oral paste), and 8.12 ± 4.24 hr (oral tablet), respectively. Maximum plasma concentration (C ) was 28.61 ± 9.29 ng/ml (oral paste) and 19.64 ± 9.26 ng/ml (oral tablet), respectively. Area under the concentration-versus-time curve (AUC ) was 336 ± 229 ng hr/ml (i.v.), 221 ± 94 ng hr/ml (oral paste), and 203 ± 139 ng hr/ml, respectively. The results showed statistically significant differences between the 2 oral vitacoxib groups in T value. T (hr), AUC (ng hr/ml), and MRT (hr) were significantly different between i.v. and oral groups. The longer half-life observed following oral administration was consistent with the flip-flop phenomenon.
三种维卡昔布制剂在马体内的药代动力学特性研究。为了描述血浆浓度并表征药代动力学,6 匹健康的成年中国蒙古马以三向、随机、平行设计的方式接受了 0.1mg/kg 体重静脉(i.v.)、口服糊剂或口服片剂维卡昔布的单次剂量。在给药前和给药后 72 小时内的不同时间采集血样。使用 UPLC-MS/MS 定量检测血浆维卡昔布浓度,并使用非房室分析计算药代动力学参数。在随后的给药中,没有注意到维卡昔布给药引起的并发症,并且所有程序在整个研究过程中都被马匹很好地耐受。消除半衰期(T )分别为 4.24±1.98 小时(i.v.)、8.77±0.91 小时(口服糊剂)和 8.12±4.24 小时(口服片剂)。最大血浆浓度(C )分别为 28.61±9.29ng/ml(口服糊剂)和 19.64±9.26ng/ml(口服片剂)。浓度-时间曲线下面积(AUC)分别为 336±229ng·hr/ml(i.v.)、221±94ng·hr/ml(口服糊剂)和 203±139ng·hr/ml。结果表明,2 种口服维卡昔布组之间 T 值存在统计学差异。T(小时)、AUC(ng·hr/ml)和 MRT(小时)在 i.v.和口服组之间存在显著差异。口服给药后观察到的半衰期延长与翻转现象一致。